Trial intelligence / Profile preview

Pramipexole in Treatment-Resistant OCD

2024-511085-37-00Phase 2Authorised

Sponsor: Centro Clínico Académico - Braga
Start: May 2024
Modality: Small Molecules
Countries: 1

Overview

Phase 2, randomised trial of pramipexole in obsessive compulsive disorder (OCD) (3 arms), sponsored by Centro Clínico Académico - Braga. Primary endpoint: Change in Y-BOCS total score from baseline to week 16 between pramipexole dose groups. Planned start May 2024; status: authorised.

Drugs

pramipexole

Conditions

obsessive compulsive disorder (OCD)

Beyond the preview

Go deeper on 2024-511085-37-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-511085-37-00.